Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4
出版年份 2019 全文链接
标题
Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4
作者
关键词
-
出版物
mAbs
Volume -, Issue -, Pages -
出版商
Informa UK Limited
发表日期
2019-06-03
DOI
10.1080/19420862.2019.1626652
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis
- (2018) K. Griffiths et al. Scientific Reports
- Antibodies to watch in 2019
- (2018) Hélène Kaplon et al. mAbs
- Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins
- (2017) Lora Hamuro et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
- (2017) Peter Bannas et al. Frontiers in Immunology
- Half-life extended biotherapeutics
- (2016) Roland E. Kontermann EXPERT OPINION ON BIOLOGICAL THERAPY
- i-bodies, Human Single Domain Antibodies That Antagonize Chemokine Receptor CXCR4
- (2016) Katherine Griffiths et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Extension of in vivo half-life of biologically active molecules by XTEN protein polymers
- (2016) Vladimir N. Podust et al. JOURNAL OF CONTROLLED RELEASE
- PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs
- (2016) Peter L. Turecek et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- PASylation of Murine Leptin Leads to Extended Plasma Half-Life and Enhanced in Vivo Efficacy
- (2015) Volker Morath et al. MOLECULAR PHARMACEUTICS
- PEGylated Biopharmaceuticals
- (2015) Inge A. Ivens et al. TOXICOLOGIC PATHOLOGY
- The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis
- (2015) Maarten Van Roy et al. ARTHRITIS RESEARCH & THERAPY
- Shark variable new antigen receptor biologics – a novel technology platform for therapeutic drug development
- (2014) Marina Kovaleva et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- GPCR-targeting nanobodies: attractive research tools, diagnostics, and therapeutics
- (2014) Azra Mujić-Delić et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Albumin as a versatile platform for drug half-life extension
- (2013) Darrell Sleep et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Site-Specific PEGylation at Histidine Tags
- (2012) Yuehua Cong et al. BIOCONJUGATE CHEMISTRY
- Strategies for extended serum half-life of protein therapeutics
- (2011) Roland E Kontermann CURRENT OPINION IN BIOTECHNOLOGY
- Plasma Half-life Extension of Small Recombinant Antibodies by Fusion to Immunoglobulin-binding Domains
- (2011) Meike Hutt et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- CXCL12 and CXCR4 in bone marrow physiology
- (2010) Natalia M Moll et al. Expert Review of Hematology
- On Setting the First Dose in Man: Quantitating Biotherapeutic Drug-Target Binding through Pharmacokinetic and Pharmacodynamic Models
- (2009) Philip J. Lowe et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Pharmacological significance of glycosylation in therapeutic proteins
- (2009) Huijuan Li et al. CURRENT OPINION IN BIOTECHNOLOGY
- Receptor-Fc fusion therapeutics, traps, and MIMETIBODY™ technology
- (2009) Chichi Huang CURRENT OPINION IN BIOTECHNOLOGY
- Kinetic screening of antibody–Im7 conjugates by capture on a colicin E7 DNase domain using optical biosensors
- (2008) Ralf J. Hosse et al. ANALYTICAL BIOCHEMISTRY
- The Impact of PEGylation on Biological Therapies
- (2008) Francesco M Veronese et al. BIODRUGS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now